key: cord-0907675-yezstn37
authors: Christensen, Rachel E.; Jafferany, Mohammad
title: Association between alopecia areata and COVID-19: A Systematic Review
date: 2022-02-10
journal: JAAD Int
DOI: 10.1016/j.jdin.2022.02.002
sha: 9b5349850cda4a52b8d044859cdb6a5d1f70f152
doc_id: 907675
cord_uid: yezstn37

Background COVID-19 may play a role in various immune-related dermatological conditions. The relationship between COVID-19 and alopecia areata remains unclear. Objective To review the existing literature for clinical studies and reports investigating the association between new-onset alopecia areata or the exacerbation of pre-existing alopecia areata following infection with SARS-CoV-2. Methods A systematic review of the literature was performed using PubMed, Embase, and MEDLINE databases from inception to October 2021. Included articles assessed alopecia areata following infection with SARS-CoV-2. Results Of 402 total articles, nine were identified as meeting inclusion criteria. Six articles described case reports of seven patients with new-onset alopecia areata following confirmed infection with SARS-CoV-2, and three articles reported on alopecia areata recurrence or exacerbation following SARS-CoV-2 infection in patients with pre-existing disease. Studies investigating the exacerbation or recurrence of alopecia areata following infection report mixed findings. Limitations A majority of included studies were case reports. Heterogeneity of articles precluded data synthesis. Conclusions Alopecia areata may be a dermatological manifestation of COVID-19, with cases most often appearing 1-2 months following infection. Additional research is necessary to better elucidate the relationship and draw conclusions.

association between new-onset alopecia areata or the exacerbation of pre-existing alopecia areata 27 following infection with SARS-CoV-2. Limitations: A majority of included studies were case reports. Heterogeneity of articles 38 precluded data synthesis. 39

The coronavirus disease (COVID-19), caused by viral infection of SARS-CoV-2, is 45 characterized by systemic activation of the immune system. Research over the past two years has 46 elucidated the relationship between COVID-19 and various immune-related dermatological conditions. 1, 2 Alopecia areata is an autoimmune disease characterized by non-scarring hair loss 48 of the scalp, face, or body that can cause severe psychological distress and affects approximately 49 2% of the population. 3 Currently, the relationship between COVID-19 and alopecia areata 50 remains unclear. A study in Turkey assessing the number of alopecia areata cases in an 51 outpatient dermatology clinic following the COVID-19 outbreak reported an increase in the 52 percentage of alopecia areata patients from 0.97% before the pandemic to 1.48% two months 53 after the pandemic. Given that alopecia areata can worsen in response to both immune 54 dysregulation and psychosocial stress, the lack of data collected in the study on infection rates 55 makes it challenging to decipher whether this increase is related to emotional distress or the virus 56

The pathophysiology of alopecia areata is not well understood, but current theories 58 involve loss of immune privilege within the hair follicle leading to a dysregulated immune 59 response. 5 As such, viruses like SARS-CoV-2 may play an important role in the development, 60 recurrence, or exacerbation of alopecia areata in infected patients. In better elucidating the 61 association, if any, between alopecia areata and COVID-19, clinicians will have the tools to 62 focus their history taking, increase the accuracy of diagnoses, and, ultimately, improve patient assessing types of non-scarring alopecia (i.e., telogen effluvium, androgenetic alopecia) and 75 scarring alopecia were not included. Studies were excluded if they were the wrong publication 76 type (i.e., letter to the editor, reviews) or in a language other than English. An independent 77 reviewer screened titles and abstracts, then full-text articles. The following data was extracted 78 from articles meeting inclusion criteria when available: study design; new-onset or exacerbation 79 of alopecia areata; patient gender; patient age; COVID-19 symptoms; treatment received for 80 COVID-19; time to alopecia areata diagnosis following COVID-19; clinical presentation of 81 alopecia areata; treatment received for alopecia areata; time to alopecia areata improvement; 82 family history of alopecia areata; patient medical history. An independent reviewer assessed risk 83 of bias in the included studies using the NIH Quality Assessment Tool for Observational Cohort 84

and Cross-Sectional Studies and the JBI Appraisal Checklist for Case Reports. 85

The PRISMA flow diagram is available in Figure 1 participants who reported contracting SARS-CoV-2, 44% reported relapse of alopecia areata at a 119 median of 2.14 months following infection compared to only 12% of COVID-negative patients 120 reporting relapse. Finally, Berbert Ferreira and colleagues reported a case of a 24-year-old 121 female with alopecia areata totalis, successfully managed with tofacitinib 5mg BID for the past 122 12 months, who tested positive for SARS-CoV-2 after experiencing loss of smell and taste. 14 123

Tofacitinib was discontinued for two weeks following diagnosis, at which point the patient 124 experienced rapid-onset and severe anagen effluvium. After two weeks, tofacitinib was restarted, 125 but the patient failed to show clinical improvement even after three months. 

Epidemiology of 177 alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis

Short-term stress-related increasing cases of 180 alopecia areata during the COVID-19 pandemic

Alopecia areata: An update on etiopathogenesis, 183 diagnosis, and management

New onset of alopecia areata in a patient with

-2 infection: Possible pathogenetic correlations

Different hair loss patterns in two pediatric 189 patients with COVID-19-associated multisystem inflammatory syndrome in 190 children

Alopecia areata in a COVID-19 patient: A 192 case report

Alopecia areata in a 196 patient with SARS-Cov-2 infection

The development of dermatologic diseases in patients recovered 199 from COVID-19

Mild-to-201 moderate COVID-19 is not associated with worsening of alopecia areata: A retrospective 202 analysis of 32 patients

Italian Survey for the Evaluation of the Effects 205 of Coronavirus Disease

Rapidly progressive alopecia areata totalis in a COVID-19 patient, 210 unresponsive to tofacitinib